Nov 15

AHA update:Vorapaxar Increases Bleeding in ACS

Giving a novel antiplatelet, vorapaxar, to acute coronary syndrome patients did not reduce mortality or serious cardiovascular events, but it did significantly increase the risk of major bleeding, including intracranial hemorrhage with a  35% increase in the relative risk of major bleeding events, and more than a three-fold increase in the risk of intracranial hemorrhage, said

Kenneth W. Mahaffey  of the Duke Clinical Research Institute in Durham, N.C., and colleagues. The trial was also published in NEJM.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>